Cancer-specific mortality in breast cancer patients with hypothyroidism: a UK population-based study

[1]  E. Guallar,et al.  Temporal patterns of chronic disease incidence after breast cancer: a nationwide population-based cohort study , 2022, Scientific Reports.

[2]  R. Sitarz,et al.  Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review , 2021, Cancers.

[3]  Kabir Yadav,et al.  Immortal Time Bias in Observational Studies. , 2021, JAMA.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  E. Balman,et al.  National Institute for Health and Care Excellence (NICE) , 2017, The Grants Register 2022.

[6]  A. Tan,et al.  Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers , 2020, Clinical Cancer Research.

[7]  O. Dekkers,et al.  Incidence of hypothyroidism after treatment for breast cancer—a Danish matched cohort study , 2020, Breast cancer research : BCR.

[8]  P. Marzullo,et al.  Incidence and prevalence of hyperthyroidism: a population-based study in the Piedmont Region, Italy , 2020, Endocrine.

[9]  B. Biondi,et al.  Thyroid hormone therapy for hypothyroidism , 2019, Endocrine.

[10]  Hamed Haghi-Aminjan,et al.  Thyroid function following breast cancer chemotherapy: A systematic review , 2019, Journal of cellular biochemistry.

[11]  M. McBride,et al.  Patterns of comorbidities in women with breast cancer: a Canadian population-based study , 2019, Cancer Causes & Control.

[12]  O. Dekkers,et al.  Hypothyroidism and the risk of breast cancer recurrence and all-cause mortality - a Danish population-based study , 2019, Breast Cancer Research.

[13]  P. Taylor,et al.  Global epidemiology of hyperthyroidism and hypothyroidism , 2018, Nature Reviews Endocrinology.

[14]  N. Roozbeh,et al.  Evaluation of thyroid gland as an organ at risk after breast cancer radiotherapy: a systematic review and meta-analysis , 2018, Clinical and Translational Oncology.

[15]  J. Hallas,et al.  Considerations for Pharmacoepidemiological Studies of Drug-Cancer Associations. , 2018, Basic & Clinical Pharmacology & Toxicology.

[16]  D. Roder,et al.  Incidence of Comorbidities in Women with Breast Cancer Treated with Tamoxifen or an Aromatase Inhibitor: An Australian Population-Based Cohort Study , 2018, Journal of comorbidity.

[17]  S. Mousa,et al.  Thyroid Hormone in the Clinic and Breast Cancer , 2018, Hormones and Cancer.

[18]  Eva Negri,et al.  Trends and predictions to 2020 in breast cancer mortality in Europe. , 2017, Breast.

[19]  P. Ellis,et al.  TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001) , 2017, European Thyroid Journal.

[20]  R. Carón,et al.  Hypothyroidism reduces mammary tumor progression via Β-catenin-activated intrinsic apoptotic pathway in rats , 2017, Histochemistry and Cell Biology.

[21]  J. Manjer,et al.  Thyroid function and survival following breast cancer , 2016, The British journal of surgery.

[22]  S. Virtanen,et al.  Iodine status in the Nordic countries – past and present , 2016, Food & nutrition research.

[23]  Marion Bennie,et al.  Data Resource Profile: The Scottish National Prescribing Information System (PIS) , 2016, International journal of epidemiology.

[24]  Carla C. Turner,et al.  Hypothyroidism in Women. , 2016, Nursing for women's health.

[25]  G. Brent,et al.  Thyroid hormone regulation of metabolism. , 2014, Physiological reviews.

[26]  J. Chang-Claude,et al.  Alcohol Consumption and Survival after a Breast Cancer Diagnosis: A Literature-Based Meta-analysis and Collaborative Analysis of Data for 29,239 Cases , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[27]  A. Sayers,et al.  Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. , 2014, JAMA internal medicine.

[28]  Mark Gurnell,et al.  Pitfalls in the measurement and interpretation of thyroid function tests☆ , 2013, Best practice & research. Clinical endocrinology & metabolism.

[29]  Cheng‐Yi Chen,et al.  Molecular Functions of Thyroid Hormones and Their Clinical Significance in Liver-Related Diseases , 2013, BioMed research international.

[30]  A. Gavin,et al.  Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002 , 2013, International journal of cancer.

[31]  F. Schellevis,et al.  Excess of health care use in general practice and of comorbid chronic conditions in cancer patients compared to controls , 2012, BMC Family Practice.

[32]  S. Dalton,et al.  Comorbidity and survival after early breast cancer. A review. , 2012, Critical reviews in oncology/hematology.

[33]  F. B. Davis,et al.  Crosstalk between Integrin αvβ3 and Estrogen Receptor-α Is Involved in Thyroid Hormone-Induced Proliferation in Human Lung Carcinoma Cells , 2011, PloS one.

[34]  D. Forman,et al.  Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study , 2011, British Journal of Cancer.

[35]  F. Frasca,et al.  Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients , 2011, PloS one.

[36]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[37]  T. Blakely,et al.  Measuring cancer survival in populations: relative survival vs cancer-specific survival. , 2010, International journal of epidemiology.

[38]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[39]  S. Fosså,et al.  Thyroid function in women after multimodal treatment for breast cancer stage II/III: comparison with controls from a population sample. , 2009, International journal of radiation oncology, biology, physics.

[40]  M. Kenward,et al.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls , 2009, BMJ : British Medical Journal.

[41]  I. White,et al.  Imputing missing covariate values for the Cox model , 2009, Statistics in medicine.

[42]  S. Pearce,et al.  Trends in thyroid hormone prescribing and consumption in the UK , 2009, BMC public health.

[43]  M. Martínez-González,et al.  Relationship between body image disturbance and incidence of depression: the SUN prospective cohort , 2009, BMC public health.

[44]  G. Booth,et al.  Autoimmune hypothyroidism and breast cancer in the elderly , 2009, Breast Cancer Research and Treatment.

[45]  W. Woodward,et al.  Risk of hypothyroidism in older breast cancer patients treated with radiation , 2008, Cancer.

[46]  E. Salazar,et al.  Effects of thyroid hormones on human breast cancer cell proliferation , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[47]  D. Stockton,et al.  Ascertainment of breast cancer by the Scottish Cancer Registry: an assessment based on comparison with five independent breast cancer trials databases. , 2008, Breast.

[48]  A. Pinchera,et al.  Favorable predictive value of thyroid autoimmunity in high aggressive breast cancer , 2007, Journal of endocrinological investigation.

[49]  Hung-Yun Lin,et al.  Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic , 2007, Steroids.

[50]  W. Demark-Wahnefried,et al.  The older cancer survivor. , 2006, Critical reviews in oncology/hematology.

[51]  G. Hortobagyi,et al.  Thyroid hormone and breast carcinoma , 2005, Cancer.

[52]  H. Quan,et al.  New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. , 2004, Journal of clinical epidemiology.

[53]  N. Mazer.  Interaction of estrogen therapy and thyroid hormone replacement in postmenopausal women. , 2004, Thyroid : official journal of the American Thyroid Association.

[54]  F. B. Davis,et al.  Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. , 2004, Endocrinology.

[55]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[56]  S. Hancock,et al.  Thyroid diseases after treatment of Hodgkin's disease. , 1991, The New England journal of medicine.

[57]  R. Hoffman,et al.  Increased Survival and Inhibition of Mammary Tumors in Hypothyroid Mice. , 1976, The Journal of surgical research.